Chan Henry Lee - 11 Aug 2026 Form 4 Insider Report for BeOne Medicines Ltd. (ONC)

Reporting relationship: SVP, General Counsel
Issuer ticker: ONC
Reported as of: 11 Aug 2026
Net transaction value: -$959,760
SEC form: 4
Accepted by SEC: 13 Aug 2026, 20:54:38 UTC
Prior SEC filing: 03 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Frank Collazo, as Attorney-in-Fact

Key filing fact

Chan Henry Lee filed Form 4 for BeOne Medicines Ltd. (ONC) on 13 Aug 2026.

Key facts

This page summarizes Chan Henry Lee's Form 4 filing for BeOne Medicines Ltd. (ONC).
7 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 13 Aug 2026, 20:54.

Change

Previous filing in this sequence was filed on 03 Aug 2026.
Current net transaction value: -$959,760.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001980648 Primary reporting owner

Lee Chan Henry

Relationship: SVP, General Counsel
Address: C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, SWITZERLAND
Signature: /s/ Frank Collazo, as Attorney-in-Fact
Signature date: 13 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ONC transaction

American Depositary Shares

Options Exercise

Transaction value
Shares: +812
Change %
Price: $194.47^*
Shares after: 812
Date: 11 Aug 2026
Ownership: Direct
Footnotes: F1

ONC transaction

American Depositary Shares

Options Exercise

Transaction value
Shares: +1,058
Change %: +130%
Price: $213.32^*
Shares after: 1,870
Date: 11 Aug 2026
Ownership: Direct
Footnotes: F1

ONC transaction

American Depositary Shares

Options Exercise

Transaction value
Shares: +796
Change %: +43%
Price: $159.03^*
Shares after: 2,666
Date: 11 Aug 2026
Ownership: Direct
Footnotes: F1

ONC transaction

American Depositary Shares

Sale

Transaction value: $959,760
Shares: -2,666
Change %: -100%
Price: $360.00
Shares after: 0
Date: 11 Aug 2026
Ownership: Direct
Footnotes: F1, F2

ONC holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 325,312
Date: 11 Aug 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ONC transaction Derivative

Share Option (Right to Buy)

Options Exercise

Transaction value
Shares: -10,556
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 11 Aug 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 10,556
Exercise price: $14.96
Footnotes: F3, F4

ONC transaction Derivative

Share Option (Right to Buy)

Options Exercise

Transaction value
Shares: -13,754
Change %: -19%
Price: $0.000000^*
Shares after: 57,369
Date: 11 Aug 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 13,754
Exercise price: $16.41
Footnotes: F3, F5

ONC transaction Derivative

Share Option (Right to Buy)

Options Exercise

Transaction value
Shares: -10,348
Change %: -10%
Price: $0.000000^*
Shares after: 88,582
Date: 11 Aug 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 10,348
Exercise price: $12.23
Footnotes: F3, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 6 footnotes

Footnote F1

Each American Depositary Share represents 13 Ordinary Shares.

Footnote F2

The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 29, 2026.

Footnote F3

The number of securities underlying each option and the exercise price therefor are represented in ordinary shares.

Footnote F4

These securities vest over a four-year period as follows: 25% on July 29, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

Footnote F5

These securities vest over a four-year period as follows: 25% on the first anniversary of June 15, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

Footnote F6

These securities vest over a four-year period as follows: 25% on the first anniversary of June 5, 2024 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.